Impact of High-to-Moderate Penetrance Genes on Genetic Testing: Looking over Breast Cancer
Genes · 2023
DOI: 10.3390/genes14081530 ↗Kurz gefasst
Fachartikel in der Zeitschrift Genes, 2023. Verfasst von Antonella Turchiano und 20 weiteren Autor:innen. Beteiligte Einrichtung: Medical Genetic, Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari "Aldo Moro", 70124 Bari, Italy. Hauptthemen laut MEDLINE: Breast Neoplasms, Kidney Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: MUR program NextGenerationEU.
Abstract (Originalsprache)
Breast cancer (BC) is the most common cancer and the leading cause of cancer death in women worldwide. Since the discovery of the highly penetrant susceptibility genes BRCA1 and BRCA2, many other predisposition genes that confer a moderate risk of BC have been identified. Advances in multigene panel testing have allowed the simultaneous sequencing of BRCA1/2 with these genes in a cost-effective way. Germline DNA from 521 cases with BC fulfilling diagnostic criteria for hereditary BC were screened with multigene NGS testing. Pathogenic (PVs) and likely pathogenic (LPVs) variants in moderate penetrance genes were identified in 15 out of 521 patients (2.9%), including 2 missense, 7 non-sense, 1 indel, and 3 splice variants, as well as two different exon deletions, as follows: ATM (n = 4), CHEK2 (n = 5), PALB2 (n = 2), RAD51C (n = 1), and RAD51D (n = 3). Moreover, the segregation analysis of PVs and LPVs into first-degree relatives allowed the detection of CHEK2 variant carriers diagnosed with in situ melanoma and clear cell renal cell carcinoma (ccRCC), respectively. Extended testing beyond BRCA1/2 identified PVs and LPVs in a further 2.9% of BC patients. In conclusion, panel testing yields more accurate genetic information for appropriate counselling, risk management, and preventive options than assessing BRCA1/2 alone.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical Genetic, Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari "Aldo Moro", 70124 Bari, Italy.
- Rare Disease Center, Internal Medicine Unit "C. Frugoni", AOU Policlinico di Bari, 70124 Bari, Italy.
- Cardiology Unit, Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari "Aldo Moro", 70124 Bari, Italy.
- Medical Genetics, National Institute of Gastroenterology, "S. de Bellis" Research Hospital, Via Turi 27, Castellana Grotte, 70013 Bari, Italy.
ORCID-Profile: Stefania Chirulli, Matteo Iacoviello, Silvia Crocetta, Cinzia Forleo, Alessandro Stella, Nenad Bukvic, Nicoletta Resta
Förderung
- MUR program NextGenerationEU
Zitieren
APA
Turchiano, A., Piglionica, M., Martino, S., Bagnulo, R., Garganese, A., De Luisi, A., Chirulli, S., Iacoviello, M., Stasi, M., Tabaku, O., Meneleo, E., Capurso, M., Crocetta, S., Lattarulo, S., Krylovska, Y., Lastella, P., Forleo, C., Stella, A., Bukvic, N., …, & Resta, N. (2023). Impact of High-to-Moderate Penetrance Genes on Genetic Testing: Looking over Breast Cancer. Genes. https://doi.org/10.3390/genes14081530
Vancouver
Turchiano A, Piglionica M, Martino S, Bagnulo R, Garganese A, De Luisi A, et al. Impact of High-to-Moderate Penetrance Genes on Genetic Testing: Looking over Breast Cancer. Genes. 2023. doi:10.3390/genes14081530
BibTeX
@article{Turchiano2023,
author = {Turchiano, Antonella and Piglionica, Marilidia and Martino, Stefania and Bagnulo, Rosanna and Garganese, Antonella and De Luisi, Annunziata and Chirulli, Stefania and Iacoviello, Matteo and Stasi, Michele and Tabaku, Ornella and Meneleo, Eleonora and Capurso, Martina and Crocetta, Silvia and Lattarulo, Simone and Krylovska, Yevheniia and Lastella, Patrizia and Forleo, Cinzia and Stella, Alessandro and Bukvic, Nenad and Simone, Cristiano and Resta, Nicoletta},
title = {Impact of High-to-Moderate Penetrance Genes on Genetic Testing: Looking over Breast Cancer},
journal = {Genes},
year = {2023},
doi = {10.3390/genes14081530}
}
EUVIMED